<!DOCTYPE html>
<html lang="en-US"><head>
		<meta charset="UTF-8">
		<title>FR940617-1-00076</title>
	</head>
	<body>
		<main>
			<p><!-- PJG STAG 4702 -->  <!-- PJG ITAG l=21 g=1 f=1 --> (5) Food and Drug Administration,  <!-- PJG 0012 frnewline --> ``General Guidelines for OTC Drug Combination  <!-- PJG 0012 frnewline --> Products,'' September 1978, Docket No.  <!-- PJG 0012 frnewline --> 78D&hyph;0322, Dockets Management Branch.  <!-- PJG /ITAG -->  <!-- PJG QTAG 04 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline -->  <!-- PJG ITAG l=11 g=1 f=1 --> 25. One comment submitted data on a combination drug  <!-- PJG 0012 frnewline --> product containing calomel (mercurous chloride) 30 percent,  <!-- PJG 0012 frnewline --> oxyquinoline benzoate, and trolamine (triethanolamine) combined  <!-- PJG 0012 frnewline --> with fatty acids to form a soap compound, plus a phenol  <!-- PJG 0012 frnewline --> derivative that is currently marketed over-the-counter and is  <!-- PJG 0012 frnewline --> indicated for use in the prevention of venereal disease (syphilis  <!-- PJG 0012 frnewline --> and gonorrhea) (Ref. 1). The comment included a historical  <!-- PJG 0012 frnewline --> review and information on in vitro activity of one of the  <!-- PJG 0012 frnewline --> ingredients. According to the comment, in 1905 the discovery was  <!-- PJG 0012 frnewline --> made that calomel in combination with fats is an effective  <!-- PJG 0012 frnewline --> germicide against  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Treponema pallidum <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  ( <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> T. pallidum <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> ), the causative  <!-- PJG 0012 frnewline --> organism of syphilis. Later, calomel was stated to be active  <!-- PJG 0012 frnewline --> against  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Neisseria gonorrhoeae <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  ( <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> N. gonorrhoeae <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> ) (the causative  <!-- PJG 0012 frnewline --> organism of gonorrhea).  <!-- PJG 0012 frnewline --> This combination of ingredients and the indication of  <!-- PJG 0012 frnewline --> prevention of syphilis and gonorrhea have not been reviewed by  <!-- PJG 0012 frnewline --> any OTC advisory review panel. However, because a claim is made  <!-- PJG 0012 frnewline --> indicating antimicrobial activity and the product contains  <!-- PJG 0012 frnewline --> calomel, which is already included in the rulemaking for OTC  <!-- PJG 0012 frnewline --> topical antimicrobial drug products, the agency believes it is  <!-- PJG 0012 frnewline --> appropriate to review this combination and labeling claim in this  <!-- PJG 0012 frnewline --> amended tentative final monograph.  <!-- PJG 0012 frnewline --> The in vitro effectiveness test described in the comment  <!-- PJG 0012 frnewline --> (Ref. 1) is a zone of inhibition test comparing the germicidal  <!-- PJG 0012 frnewline --> activity of calomel, phenol, and organic silver salts against  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> S. aureus  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> as an indicator of activity against syphilis ( <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> T.  <!-- PJG 0012 frnewline --> pallidum <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> ) and gonorrhea ( <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> N. gonorrhoeae <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> ). According to the  <!-- PJG 0012 frnewline --> submission, the causative organisms are not viable in vitro and  <!-- PJG 0012 frnewline --> were not used in the testing. The agency points out that it is  <!-- PJG 0012 frnewline --> possible to isolate and subculture isolates of  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> N. gonorrhoeae <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  for  <!-- PJG 0012 frnewline --> in vitro antimicrobial testing (Ref. 2), but  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> T. pallidum  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> cannot  <!-- PJG 0012 frnewline --> be grown in vitro (Ref. 3). The agency does not consider the in  <!-- PJG 0012 frnewline --> vitro test against  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> S. aureus <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  to be adequate to support a claim of  <!-- PJG 0012 frnewline --> prevention of syphilis and gonorrhea.  <!-- PJG 0012 frnewline --> In a separate rulemaking for mercury-containing drug  <!-- PJG 0012 frnewline --> products for topical antimicrobial use, calomel was reviewed by  <!-- PJG 0012 frnewline --> the Miscellaneous External Panel (47 FR 436 at 440). That Panel  <!-- PJG 0012 frnewline --> did note that calomel ``has been used in the past by inunction  <!-- PJG 0012 frnewline --> (rubbing into the skin) as a prophylactic against venereal  <!-- PJG 0012 frnewline --> disease *&blank;*&blank;*'' but placed the ingredient in Category II because  <!-- PJG 0012 frnewline --> ``calomel may be safe as a topical antimicrobial agent, but it is  <!-- PJG 0012 frnewline --> not effective for this purpose.''  <!-- PJG 0012 frnewline --> Although it is apparent that calomel 30 percent would be  <!-- PJG 0012 frnewline --> considered an active ingredient, it is not clear from the  <!-- PJG 0012 frnewline --> available information whether the other ingredients in the  <!-- PJG 0012 frnewline --> combination (oxyquinoline benzoate, trolamine, and phenol  <!-- PJG 0012 frnewline --> derivative) are also considered active ingredients, nor are the  <!-- PJG 0012 frnewline --> concentrations of these other ingredients stated in the submission and no data have been submitted to the OTC drug review  <!-- PJG 0012 frnewline --> on these ingredients in relation to the prevention of venereal  <!-- PJG 0012 frnewline --> disease. In the absence of any data, none of these ingredients  <!-- PJG 0012 frnewline --> are considered safe and effective for this use.  <!-- PJG 0012 frnewline --> The comment did not submit any in vivo data from clinical  <!-- PJG 0012 frnewline --> studies to demonstrate that the combination of calomel,  <!-- PJG 0012 frnewline --> oxyquinoline benzoate, trolamine, and phenol derivative is safe  <!-- PJG 0012 frnewline --> and effective for use in the prevention of syphilis and  <!-- PJG 0012 frnewline --> gonorrhea. Preliminary in vitro testing against  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> N. gonorrhoeae  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  <!-- PJG 0012 frnewline --> should be conducted before any human clinical trials are done.  <!-- PJG 0012 frnewline --> Then, favorable results from two well-controlled clinical studies  <!-- PJG 0012 frnewline --> in humans conducted by qualified investigators in two geographic  <!-- PJG 0012 frnewline --> locations (at least one should be within the United States of  <!-- PJG 0012 frnewline --> America) are needed before any drug product can be recognized to  <!-- PJG 0012 frnewline --> be safe and effective in preventing syphilis and gonorrhea.  <!-- PJG 0012 frnewline --> Interested individuals should consult with the agency before  <!-- PJG 0012 frnewline --> initiating any testing. In conclusion, the agency is proposing  <!-- PJG 0012 frnewline --> that this combination of ingredients indicated for the prevention  <!-- PJG 0012 frnewline --> of syphilis and gonorrhea be classified Category II in this  <!-- PJG 0012 frnewline --> amended tentative final monograph.  <!-- PJG 0012 frnewline --> The agency's detailed comments and evaluation on the data  <!-- PJG 0012 frnewline --> are on file in the Dockets Management Branch (Ref. 4).  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->   <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=74 g=1 f=1 --> References  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=21 g=1 f=1 --> (1) Comment No. C158, Docket No.  <!-- PJG 0012 frnewline --> 75N&hyph;0183, Dockets Management Branch.  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG /STAG --></p>
		</main>
</body></html>
            